Oncologix Tech Stock Short Ratio
| OCLG Stock | USD 0.0001 0.00 0.00% |
Oncologix Tech fundamentals help investors to digest information that contributes to Oncologix Tech's financial success or failures. It also enables traders to predict the movement of Oncologix Pink Sheet. The fundamental analysis module provides a way to measure Oncologix Tech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncologix Tech pink sheet.
Oncologix |
Oncologix Tech Company Short Ratio Analysis
Oncologix Tech's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Oncologix Tech has a Short Ratio of 0.0 times. This is 100.0% lower than that of the Health Care Providers & Services sector and about the same as Health Care (which currently averages 0.0) industry. The short ratio for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Insider Screener Now
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |
| All Next | Launch Module |
Oncologix Fundamentals
| Return On Asset | -0.12 | |||
| Profit Margin | (0.38) % | |||
| Operating Margin | (0.13) % | |||
| Current Valuation | 3.18 M | |||
| Shares Outstanding | 340.13 M | |||
| Price To Earning | (0.03) X | |||
| Price To Sales | 0.17 X | |||
| Revenue | 2.85 M | |||
| Gross Profit | 614.41 K | |||
| EBITDA | (572.25 K) | |||
| Net Income | (2.37 M) | |||
| Cash And Equivalents | 86.31 K | |||
| Total Debt | 3.97 M | |||
| Current Ratio | 0.28 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (24.2 K) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 191 | |||
| Beta | 1.27 | |||
| Market Capitalization | 612.23 K | |||
| Total Asset | 1.5 M | |||
| Retained Earnings | (49.86 M) | |||
| Working Capital | (3.35 M) | |||
| Current Asset | 1.31 M | |||
| Current Liabilities | 4.67 M | |||
| Z Score | -47.6 | |||
| Net Asset | 1.5 M |
About Oncologix Tech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncologix Tech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncologix Tech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncologix Tech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Oncologix Pink Sheet
Oncologix Tech financial ratios help investors to determine whether Oncologix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncologix with respect to the benefits of owning Oncologix Tech security.